Drugs / Pidilizumab
Pidilizumab
also known as
CT-011 · anti-PD-1 antibody · MDV9300 · KRAS Neoantigen Nanovaccine · Monoclonal Antibody CT-011
Monoclonal antibody targets GPC3, KRAS, PDCD1 via inhibition
Trials 16 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01435369 Comparator | Nov 2011 → Aug 2013 | melanoma | Medivation, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01441765 Comparator | Nov 2011 → Jul 2016 | renal cell carcinoma | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01067287 Comparator | Mar 2010 → Sep 2025 | plasma cell myeloma | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-05-17 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and CureTech Announce Positive Phase II Data From CT-011, an Investigational Antibody in Diffuse Large B Cell Lymphoma tevapharm.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pidilizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02530125 ↗ |
| Known as | anti-PD-1 antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04004234 ↗ |
| Known as | CT-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00532259 ↗ |
| Known as | KRAS Neoantigen Nanovaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07353645 ↗ |
| Known as | MDV9300 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02653989 ↗ |
| Known as | Monoclonal Antibody CT-011 | “Monoclonal Antibody CT-011” NCT00904722 ↗ |
| Action | Inhibit | “blocks the interaction of PD-L1 with PD-1” NCT01313416 ↗ |
| Modality | Monoclonal antibody | “the monoclonal antibody, CT-011” NCT00890305 ↗ |
| Route | Intravenous | “IV infusion of 1.5 mg/kg of CT-011” NCT00532259 ↗ |
| Target | PDCD1 | “CT-011 is a humanized immunoglobulin G 1 (IgG1) kappa recombinant monoclonal antibody against PD-1 receptor” NCT01313416 ↗ |